{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:02:15Z","timestamp":1792425735322,"version":"4.5.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immunoglobulin G (IgG) levels are maintained by the IgG-recycling neonatal Fc-receptor (FcRn). Pemphigus vulgaris and pemphigus foliaceus are debilitating autoimmune disorders triggered by IgG autoantibodies against mucosal and epidermal desmogleins. Recently, a phase 2 clinical trial (NCT03334058;<jats:uri>https:\/\/clinicaltrials.gov\/NCT03334058<\/jats:uri>) was completed in participants with pemphigus using efgartigimod, an FcRn inhibitor, in combination with prednisone. Efgartigimod demonstrated an early effect on diease activity and was well tolerated. In addition to the safety and efficacy assessment, clinical trials present an opportunity to gain more insights into the mechanism of disease, the mode of action of treatment, and potential for corticosteroid-sparing activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of our study was to assess the impact of FcRn antagonism by efgartigimod on immunological parameters known to be directly involved in pemphigus pathology, such as cellular and serological responses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We investigated total and antigen-specific IgG subclass level kinetics during\u00a0and after treatment, assessed antigen-specific B-cell responses, followed T- and B-cell immunophenotypes, and analyzed how different immunophenotypes link to clinical\u00a0response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment resulted in reduction of total IgG as well as autoreactive IgG antibody levels. Surprisingly, unlike total IgG and vaccine- or natural-infection-elicited IgG, which returned to baseline levels after stopping efgartigimod treatment, autoreactive antibody levels remained low in several study participants. Efgartigimod showed no effect on total leukocytes, neutrophils, monocytes, or lymphocytes in patients treated with extended efgartigimod therapy. Intriguingly, antigen-specific analyses revealed a loss of desmoglein-specific B cells in several participants responding to efgartigimod, in line with prolonged reduction of pathogenic IgG levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Efgartigimod treatment of participants with pemphigus improved their conditions and exerted an immunomodulatory effect beyond the blockade of IgG recycling. Further studies in larger populations with an appropriate placebo control are needed to confirm these potentially important observations to establish long-term clinical responses in autoimmune diseases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.863095","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T05:40:46Z","timestamp":1652852446000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus"],"prefix":"10.3389","volume":"13","author":[{"given":"Maud","family":"Maho-Vaillant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Sips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Golinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gestur","family":"Vidarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Stoevesandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Bata-Cs\u00f6rg\u0151","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Balbino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Verheesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Calbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s1568-9972(03)00006-5","article-title":"The Epidemiology of Autoimmune Diseases","volume":"2","author":"Cooper","year":"2003","journal-title":"Autoimmun Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2007.05.002","article-title":"Epidemiology of Autoimmune Diseases in Denmark","volume":"29","author":"Eaton","year":"2007","journal-title":"J Autoimmun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B Cells and Plasma Cells in Autoimmune Diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"French Study Group on Autoimmune Bullous Skin D. First-Line Rituximab Combined With Short-Term Prednisone Versus Prednisone Alone for the Treatment of Pemphigus (Ritux 3): A Prospective, Multicentre, Parallel-Group, Open-Label Randomised Trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab Versus Mycophenolate Mofetil in Patients With Pemphigus Vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.1086907","article-title":"Predominant Autoantibody Production by Early Human B Cell Precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.11.008","article-title":"Immunophenotyping in Pemphigus Reveals a TH17\/TFH17 Cell-Dominated Immune Response Promoting Desmoglein1\/3-Specific Autoantibody Production","volume":"147","author":"Holstein","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28547","article-title":"T Cell Control in Autoimmune Bullous Skin Disorders","volume":"116","author":"Hertl","year":"2006","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.172","article-title":"Rituximab Exerts a Dual Effect in Pemphigus Vulgaris","volume":"128","author":"Eming","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.27","article-title":"Rituximab Mediates a Strong Elevation of B-Cell-Activating Factor Associated With Increased Pathogen-Specific IgG But Not Autoantibodies in Pemphigus Vulgaris","volume":"129","author":"Nagel","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6064\/2012\/215308","article-title":"B Cell in Autoimmune Diseases","volume":"2012","author":"Hampe","year":"2012","journal-title":"Sci (Cairo)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000825","article-title":"Immune Checkpoints and the Multiple Faces of B Cells in Systemic Lupus Erythematosus","volume":"33","author":"Stefanski","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01375","article-title":"Identification of Autoreactive B Cell Subpopulations in Peripheral Blood of Autoimmune Patients With Pemphigus Vulgaris","volume":"10","author":"Pollmann","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.10.008","article-title":"The Long and the Short of it: Insights Into the Cellular Source of Autoantibodies as Revealed by B Cell Depletion Therapy","volume":"55","author":"Hale","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of Autoantibody-Induced Pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2001.5115","article-title":"Generation of CD4(+) and CD8(+) T Lymphocyte Responses by Dendritic Cells Armed With PSA\/anti-PSA (Antigen\/Antibody) Complexes","volume":"101","author":"Berlyn","year":"2001","journal-title":"Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01393","article-title":"Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation","volume":"11","author":"Junker","year":"2020","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00408","article-title":"The Role of FcRn in Antigen Presentation","volume":"5","author":"Baker","year":"2014","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.imlet.2021.06.006","article-title":"New Aspects in the Regulation of Human B Cell Functions by Complement Receptors CR1, CR2, CR3 and CR4","volume":"237","author":"Erdei","year":"2021","journal-title":"Immunol Lett"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00544-w","article-title":"Novel Therapies for Pemphigus Vulgaris","volume":"21","author":"Altman","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30","article-title":"A Practical Guide to the Monitoring and Management of the Complications of Systemic Corticosteroid Therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1002\/j.1875-9114.1991.tb02641.x","article-title":"Complications Associated With Immunosuppressive Therapy and Their Management","volume":"11","author":"Min","year":"1991","journal-title":"Pharmacotherapy"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc Region of Immunoglobulin G to Modulate In Vivo Antibody Levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat Biotechnol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc Receptor Antagonist Efgartigimod Safely and Sustainably Reduces IgGs in Humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized Phase 2 Study of FcRn Antagonist Efgartigimod in Generalized Myasthenia Gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 Study of Efgartigimod, A Novel FcRn Antagonist, in Adult Patients With Primary Immune Thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20782","article-title":"Treatment of Pemphigus Vulgaris and Foliaceus With Efgartigimod, A Neonatal Fc Receptor Inhibitor: A Phase 2 Multicentre, Open-Label Feasibility Trial","volume":"186","author":"Goebeler","year":"2021","journal-title":"Br J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.04.042","article-title":"Large International Validation of ABSIS and PDAI Pemphigus Severity Scores","volume":"139","author":"Hebert","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.603931","article-title":"Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay","volume":"11","author":"Drouot","year":"2020","journal-title":"Front Microbiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2006.00451.x","article-title":"IgG Reactivity Against non-Conformational NH-Terminal Epitopes of the Desmoglein 3 Ectodomain Relates to Clinical Activity and Phenotype of Pemphigus Vulgaris","volume":"15","author":"Muller","year":"2006","journal-title":"Exp Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.01.031","article-title":"Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus","volume":"141","author":"Maho-Vaillant","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus Statement on Definitions of Disease, End Points, and Therapeutic Response for Pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/s0923-1811(00)00158-4","article-title":"Predominant IgG4 Subclass in Autoantibodies of Pemphigus Vulgaris and Foliaceus","volume":"26","author":"Futei","year":"2001","journal-title":"J Dermatol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in Humans Reduces Circulating IgG Levels and Inhibits IgG Immune Complex-Mediated Immune Responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci Adv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02824","article-title":"Neutrophil Extracellular Traps in Autoimmunity and Allergy: Immune Complexes at Work","volume":"10","author":"Granger","year":"2019","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.celrep.2019.06.066","article-title":"Single-Cell Analysis Suggests That Ongoing Affinity Maturation Drives the Emergence of Pemphigus Vulgaris Autoimmune Disease","volume":"28","author":"Cho","year":"2019","journal-title":"Cell Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan8405","article-title":"Circulating TFH Cells, Serological Memory, and Tissue Compartmentalization Shape Human Influenza-Specific B Cell Immunity","volume":"10","author":"Koutsakos","year":"2018","journal-title":"Sci Transl Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.032","article-title":"Pivotal Role of Lesional and Perilesional T\/B Lymphocytes in Pemphigus Pathogenesis","volume":"137","author":"Yuan","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-017-8662-z","article-title":"Pemphigus: A Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches","volume":"54","author":"Pollmann","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.jid.2021.04.031","article-title":"3rd. Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus","volume":"141","author":"Werth","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-Term Remissions of Severe Pemphigus After Rituximab Therapy are Associated With Prolonged Failure of Desmoglein B Cell Response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA Testing of Anti-Desmoglein 1 and 3 Antibodies in the Management of Pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0290","article-title":"French Study Group on Autoimmune Bullous Skin D. Factors Associated With Short-Term Relapse in Patients With Pemphigus Who Receive Rituximab as First-Line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial","volume":"156","author":"Mignard","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24185","article-title":"Genetic and Functional Characterization of Human Pemphigus Vulgaris Monoclonal Autoantibodies Isolated by Phage Display","volume":"115","author":"Payne","year":"2005","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01477","article-title":"Complement Activation in Autoimmune Bullous Dermatoses: A Comprehensive Review","volume":"10","author":"Edwards","year":"2019","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-151-39267","article-title":"Serum and Blister Fluid Anticomplementary Activity in Pemphigus and Bullous Pemphigoid. Sucrose Density Gradient Studies","volume":"151","author":"Jordon","year":"1976","journal-title":"Proc Soc Exp Biol Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/bit.26545","article-title":"Enrichment of High Affinity Subclasses and Glycoforms From Serum-Derived IgG Using FcgammaRs as Affinity Ligands","volume":"115","author":"Boesch","year":"2018","journal-title":"Biotechnol Bioeng"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700116","article-title":"Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcgamma Receptor Profile","volume":"199","author":"Bruggeman","year":"2017","journal-title":"J Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2909","article-title":"Fc Receptor-Targeted Therapies for the Treatment of Inflammation, Cancer and Beyond","volume":"11","author":"Hogarth","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1699-0463.1993.tb00117.x","article-title":"Tissue Distribution of Human IgG Fc Receptors CD16, CD32 and CD64: An Immunohistochemical Study","volume":"101","author":"Tuijnman","year":"1993","journal-title":"APMIS"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.178","article-title":"B-Cell Depletion Immunotherapy in Pemphigus: Effects on Cellular and Humoral Immune Responses","volume":"128","author":"Mouquet","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01794","article-title":"Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen","volume":"10","author":"Hebert","year":"2019","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211045049","article-title":"Neonatal Fc Receptor Expression in Lymphoid and Myeloid Cells in Systemic Lupus Erythematosus","volume":"12","author":"Yanis","year":"2021","journal-title":"Lupus"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.11.7550","article-title":"Targeting the Neonatal Fc Receptor for Antigen Delivery Using Engineered Fc Fragments","volume":"181","author":"Mi","year":"2008","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2015.76","article-title":"Prednisone Treatment Inhibits the Differentiation of B Lymphocytes Into Plasma Cells in MRL\/MpSlac-Lpr Mice","volume":"36","author":"Yan","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"B57","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.clim.2007.10.004","article-title":"A Novel Subset of Memory B Cells is Enriched in Autoreactivity and Correlates With Adverse Outcomes in SLE","volume":"126","author":"Nicholas","year":"2008","journal-title":"Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1078\/0171-2985-00198","article-title":"Expansion of CD19(hi)CD21(lo\/neg) B Cells in Common Variable Immunodeficiency (CVID) Patients With Autoimmune Cytopenia","volume":"206","author":"Warnatz","year":"2002","journal-title":"Immunobiology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-243071","article-title":"Complement Receptor 2\/CD21- Human Naive B Cells Contain Mostly Autoreactive Unresponsive Clones","volume":"115","author":"Isnardi","year":"2010","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"13921","DOI":"10.1038\/s41598-017-14089-2","article-title":"Peripheral CD19(hi) B Cells Exhibit Activated Phenotype and Functionality in Promoting IgG and IgM Production in Human Autoimmune Diseases","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00032","article-title":"CD11c(+) B Cells Are Mainly Memory Cells, Precursors of Antibody Secreting Cells in Healthy Donors","volume":"11","author":"Golinski","year":"2020","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20431","article-title":"Investigators Bt. Proof of Concept for the Clinical Effects of Oral Rilzabrutinib, the First Bruton Tyrosine Kinase Inhibitor for Pemphigus Vulgaris: The Phase II BELIEVE Study","volume":"185","author":"Murrell","year":"2021","journal-title":"Br J Dermatol"},{"key":"B63","volume-title":"Sanofi Provides Update on Phase 3 Study Evaluating Rilzabrutinib for the Treatment of Pemphigus","year":"2021"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.863095\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T19:29:38Z","timestamp":1700594978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.863095\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2022.863095"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.863095","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"article-number":"863095"}}